SAN DIEGO -- SynteractHCR, a leading full-service contract research organization (CRO), has hired two new senior executives to support the company's growth on a global scale following its recent merger. SynteractHCR has appointed Bill Pierce as chief information officer and Richard Paul as chief medical officer and vice president medical/regulatory affairs. Both were chosen for their leadership experience and expertise in their respective fields; Pierce has held key leadership positions within the CRO as well as financial industries, and Paul has more than 23 years of drug development experience across several therapeutic areas.
As CIO, Pierce will be responsible for driving operational excellence, streamlining processes and delivering high returns for invested capital. He brings a strong foundation in the CRO industry and is very experienced across clinical data management platforms and technologies. He gained leadership experience across various industries, including his last position at INC Research as chief information officer. Previously he served as vice president both for Fidelity Investments and Goldman Sachs, among other leadership positions. Pierce received his degree from Boston University.
In his role as CMO, Dr. Paul will be providing global leadership and oversight for medical safety and regulatory affairs. He brings more than 23 years of clinical research, regulatory affairs, medical safety and strategic drug development experience to his new role. Prior to joining SynteractHCR, Paul held positions with QRxPharma as executive vice president of drug development where he had global responsibility for clinical research and regulatory affairs. He also served as senior vice president of global regulatory affairs at ICON Clinical Research. Paul earned his MD degree from the University of Barcelona and conducted his postgraduate medical training at Rutgers University and Harvard School of Medicine.
According to Wendel Barr , CEO of SynteractHCR, the two new hires will be instrumental in driving the company's plans for growth to meet the increasingly complex needs of its clients.
"After two decades of operations, we are known for offering our clients individualized services tailored to their specific needs. With their impressive industry experience, Bill and Richard provide additional valuable assets to our company. Leading our Information Technology group, Bill will leverage technology to drive efficiency across the projects we support and overall business productivity. Paul's expertise in medical, safety, drug development and regulatory affairs will ensure that across the continuum of our service offering, we maintain the highest quality standards with product approval the objective. I am certain that as excellent leaders, Bill and Rich will help the company grow, to further expand our offerings on a global scale."
SynteractHCR has been formed from the merger of Synteract and Harrison Clinical Research (HCR), announced earlier this month. The newly expanded company operates from 16 locations worldwide and will provide top tier international capabilities to support clinical trials globally, from emerging products through post-marketing.
About SynteractHCR (www.synteracthcr.com)
SynteractHCR is a full-service contract research organization with a successful two-decade track record supporting biotechnology, medical device and pharmaceutical companies in all phases of clinical development. With its "Shared Work – Shared Vision" philosophy SynteractHCR provides customized Phase I through IV services collaboratively and cost effectively ensuring on-time delivery of quality data so clients get to decision points faster. Operating in 16 countries, SynteractHCR delivers trials internationally, offering expertise across multiple therapeutic areas including notable depth in oncology, CNS, infectious disease, endocrinology, cardiovascular and respiratory, among other indications.